MG
IMVT icon

Marex Group’s Immunovant IMVT Stock Holding History

Marex Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$397K Buy
+16,000
New +$414K ﹤0.01% 691

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Marex Group's IMVT Position: Q1 2026 in Review

Marex Group opened a new position in Immunovant (IMVT) in Q1 2026: 16,000 shares worth $397K. The stake represents ﹤0.01% of the portfolio and ranks #691 among its holdings.

215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Marex Group held 16,000 shares of Immunovant worth $397K as of Q1 2026.
  • Immunovant was a new Marex Group position in Q1 2026.
  • Immunovant made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #691 holding.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.